Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

NCT07397819 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Malignant Ascites

Interventions

DRUG: liposomal irinotecan monotherapy
DRUG: liposomal irinotecan monotherapy
DRUG: Liposomal Irinotecan + rmhTNF-NC
DRUG: Liposomal Irinotecan + Bevacizumab

Sponsor

Dong sheng Zhang

Collaborators

[object Object]